NASDAQ · Biotechnology

Bright Minds Biosciences Inc. (DRUG) Stock

$54.05 +3.94% NASDAQ: DRUG Healthcare

Valuation

MetricValue
Price$54.05
Market Cap$529.00M
P/E Ratio-31.76
P/B Ratio2.94
P/S Ratio0.00
EPS (TTM)$-10.64
52-Week High$123.75
52-Week Low$39.70
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-12.56%
ROA-7.96%
ROCE-17.07%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio42.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-9.0M$-15.0M$-7.0M$-3.0M$-14.0M
Net Profit$-9.0M$-15.0M$-7.0M$-3.0M$-12.0M
EPS$-4.74$-6.15$-1.98$-0.65$-1.78
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$20.0M$12.0M$7.0M$6.0M$84.0M
Total Liabilities$1.0M$2.0M$0$1.0M$2.0M
Cash$20.0M$12.0M$7.0M$6.0M$83.0M
Borrowings$0$0$0$0$0

Latest News

All You Need to Know About Bright Minds Biosciences Inc. (DRUG) Rating Upgrade to Strong Buy Zacks · Jul 22, 2026 Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline Motley Fool · May 21, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-7.0M$-14.0M$-7.0M$-2.0M$-9.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$-2.0M$1.0M$1.0M$0$0
Net Cash Flow$19.0M$-8.0M$-5.0M$-1.0M$77.0M
Free Cash Flow$-7.0M$-14.0M$-7.0M$-2.0M$-9.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.43
EV / EBITDA-40.98
FCF Yield-1.85%
Quick Ratio36.10
Interest Coverage-2336.36
Return 1Y138.59%
Return 3Y1816.40%
Return 5Y229.02%

Ownership

Insiders Held12.00%
Institutions Held93.00%
Institutions Float Held105.69%
Institutional HolderSharesReport Date
Janus Henderson Group PLC1,284,3242026-03-31
Cormorant Asset Management, LP1,059,3312026-03-31
Blackrock Inc.621,9332026-03-31
Vivo Capital, LLC557,1722026-03-31
Braidwell LP 539,7082026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BETR.CNBetterLife Pharma Inc. $0.28 +3.70% -30.00 $51.03M 0.00%
BNXT.CNBioNxt Solutions Inc. $0.33 -13.16% -4.86 $47.63M 0.00%
CYBN.NECybin Inc. — — — — 0.00%
LOBE.CNLobe Sciences Ltd. $0.05 -16.67% -2.25 $24.65M 0.00%
MRVL.VMarvel Biosciences Corp. $0.12 +0.00% -4.67 $8.82M 0.00%

About Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc. is led by CEO Ian McDonald, employs 26 people, headquartered in CA, publicly traded since 2021.

Bright Minds Biosciences Inc. (DRUG) stock trades at $54.05 with a market capitalization of $529.00M. The stock is valued at a price-to-earnings (P/E) ratio of -31.76, price-to-book of 2.94, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $39.70 and $123.75, and currently trades 56.3% below its 52-week high.

On profitability, Bright Minds Biosciences Inc. generates a return on equity (ROE) of -12.56%, return on capital employed of -17.07%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides